DEUTERONCOLOGY

DeuterOncology NV was founded in September 2020 by Dr Timothy Perera and is based in Liege in Belgium. The company generated pre-clinical validation of DO-2, a novel, highly selective, brain penetrant deuterated MET kinase and RAS pathway inhibitor.

Also known as: DeuterOncology NV